BR112022014456A2 - Tafoxiparina para o tratamento da pré-eclâmpsia - Google Patents

Tafoxiparina para o tratamento da pré-eclâmpsia

Info

Publication number
BR112022014456A2
BR112022014456A2 BR112022014456A BR112022014456A BR112022014456A2 BR 112022014456 A2 BR112022014456 A2 BR 112022014456A2 BR 112022014456 A BR112022014456 A BR 112022014456A BR 112022014456 A BR112022014456 A BR 112022014456A BR 112022014456 A2 BR112022014456 A2 BR 112022014456A2
Authority
BR
Brazil
Prior art keywords
tafoxiparin
preeclampsia
treatment
combination
therapy
Prior art date
Application number
BR112022014456A
Other languages
English (en)
Inventor
Degling-Wikingsson Lena
Ekman-Ordeberg Gunvor
Hansson Stefan
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of BR112022014456A2 publication Critical patent/BR112022014456A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

TAFOXIPARINA PARA O TRATAMENTO DA PRÉ-ECLÂMPSIA. A presente invenção refere-se ao uso do derivado de heparina tafoxiparina no tratamento da pré-eclâmpsia (PE). O tratamento pode ser monoterapia ou terapia combinada, em que a tafoxiparina é usada em combinação com um agente (fármaco) usado como terapia padrão de cuidados na pré-eclâmpsia (PE).
BR112022014456A 2020-02-17 2021-02-16 Tafoxiparina para o tratamento da pré-eclâmpsia BR112022014456A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2000033 2020-02-17
PCT/EP2021/053733 WO2021165240A1 (en) 2020-02-17 2021-02-16 Tafoxiparin for the treatment of preeclampsia

Publications (1)

Publication Number Publication Date
BR112022014456A2 true BR112022014456A2 (pt) 2022-09-13

Family

ID=74668828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014456A BR112022014456A2 (pt) 2020-02-17 2021-02-16 Tafoxiparina para o tratamento da pré-eclâmpsia

Country Status (13)

Country Link
US (1) US20230144378A1 (pt)
EP (1) EP4106765A1 (pt)
JP (1) JP2023512920A (pt)
KR (1) KR20220142508A (pt)
CN (1) CN115103679A (pt)
AU (1) AU2021223494A1 (pt)
BR (1) BR112022014456A2 (pt)
CA (1) CA3169421A1 (pt)
CL (1) CL2022002239A1 (pt)
CO (1) CO2022013055A2 (pt)
IL (1) IL295184A (pt)
MX (1) MX2022010093A (pt)
WO (1) WO2021165240A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
AR129190A1 (es) 2022-05-03 2024-07-31 Dilafor Ab Nuevo uso médico de la tafoxiparina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
RS56874B1 (sr) 2011-12-19 2018-04-30 Dilafor Ab Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
RU2014143017A (ru) 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов
RU2014143008A (ru) 2012-03-26 2016-05-20 Дилафор Аб Способ лечения остановки родов
UA117912C2 (uk) 2012-05-08 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для лікування післяпологової кровотечі (ппк)
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes

Also Published As

Publication number Publication date
WO2021165240A1 (en) 2021-08-26
IL295184A (en) 2022-09-01
MX2022010093A (es) 2022-09-02
CL2022002239A1 (es) 2023-04-10
US20230144378A1 (en) 2023-05-11
AU2021223494A1 (en) 2022-08-04
EP4106765A1 (en) 2022-12-28
JP2023512920A (ja) 2023-03-30
CA3169421A1 (en) 2021-08-26
CO2022013055A2 (es) 2022-09-30
CN115103679A (zh) 2022-09-23
KR20220142508A (ko) 2022-10-21

Similar Documents

Publication Publication Date Title
BR112022014456A2 (pt) Tafoxiparina para o tratamento da pré-eclâmpsia
BR112016014830A2 (pt) Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112017026746A2 (pt) composições de liberação de fármacos implantáveis e métodos de uso dos mesmos
BR112018076639A2 (pt) quimioterapias de combinação
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112016013961A2 (pt) angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112014016950A2 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR112013010325A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
BR112022013741A2 (pt) Composição farmacêutica
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção